TG Therapeutics, Inc. (TGTX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases. Its primary commercial product is BRIUMVI (ublituximab), approved for relapsing forms of multiple sclerosis (RMS) in the U.S., EU, and UK. The company is also advancing azer-cel (azercabtagene zapreleucel) for autoimmune indications following a license agreement with Precision BioSciences.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $73,466 | $16,074 | $136,939 | $23,877 |
| Net Income (Loss) | $6,879 | $(47,610) | $(3,828) | $(86,841) |
| Operating Income (Loss) | $8,816 | $(44,674) | $(454) | $(81,665) |
| Cash & Equivalents | $82,910 | $92,933 | As of June 30, 2024 | |
| Investment Securities | $135,289 | $124,575 | As of June 30, 2024 | |
| Total Liquidity | $217,300 | Combined cash and investments | ||
| Loan Payable (Non-current) | $102,537 | $100,118 | As of June 30, 2024 |
Note: Q2 2024 marked the company's first quarterly net profit since inception, driven by significant revenue growth from BRIUMVI.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 357% year-over-year in Q2 2024 ($73.5M vs. $16.1M). Product revenue from BRIUMVI grew to $72.6M from $16.0M, driven by increased market penetration in the U.S.
- Profitability: The company reported a net income of $6.9M in Q2 2024, a reversal from a net loss of $47.6M in Q2 2023. Operating income turned positive at $8.8M.
- Expense Management: Research and Development (R&D) expenses decreased to $17.6M in Q2 2024 from $28.1M in Q2 2023, primarily due to reduced clinical trial costs and lower non-cash compensation. However, Selling, General, and Administrative (SG&A) expenses increased to $38.8M from $30.7M due to commercialization scaling.
- Inventory Buildup: Inventory increased significantly to $81.2M (from $39.8M at year-end 2023) to support forecasted sales and supply commitments to partner Neuraxpharm.
Guidance, Outlook, and Risks
- Outlook: Management believes existing cash, investments, and projected BRIUMVI revenues will fund operations for at least 12 months. The company expects gross margins to decrease modestly after Q1 2025 as pre-commercialization inventory is depleted.
- Subsequent Events (August 2024):
- Refinanced existing Hercules debt with a new $250 million term loan from Blue Owl Capital/HealthCare Royalty.
- Authorized a $100 million share repurchase program.
- Initiated a Phase 1 trial for subcutaneous ublituximab and received FDA IND clearance for azer-cel in progressive MS.
- Risks & Contingencies:
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to non-routine share-based payment awards. Remediation is expected by year-end 2024.
- Commercialization: Success depends on market acceptance of BRIUMVI and the ability of partner Neuraxpharm to execute EU/UK launches.
- Regulatory: Risks include potential side effects, post-marketing requirements, and pricing pressures from government programs (e.g., Inflation Reduction Act).
Investor Verification Checklist
- Debt Refinancing Terms: Verify the specific interest rates, covenants, and amortization schedule of the new $250M Blue Owl facility announced in August 2024.
- Gross Margin Trajectory: Monitor the depletion of pre-commercialization inventory and the resulting impact on cost of revenue and gross margins starting Q1 2025.
- Internal Control Remediation: Confirm the implementation and testing of new controls regarding share-based compensation to resolve the identified material weakness.
- Neuraxpharm Performance: Track the commercial launch progress of BRIUMVI in EU markets outside of Germany and the associated royalty/milestone revenue recognition.
- Share Repurchase Execution: Monitor the pace and pricing of the newly authorized $100M buyback program.